共 50 条
- [3] Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (06): : 842 - 852
- [5] POWER (Porphyria Worldwide Patient Experience Research) Study: Impact of Acute Hepatic Porphyria Assessed Through an International Patient Survey AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S577 - S577
- [7] ERYTHROPOIETIN FOR THE TREATMENT OF PORPHYRIA CUTANEA-TARDA IN A PATIENT ON LONG-TERM HEMODIALYSIS NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (05): : 315 - 317
- [10] The Impact of Acute Hepatic Porphyria on Mental Health: Results From the Porphyria Worldwide Patient Experience Research (POWER) Study AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S966 - S966